Leichsenring, Jonas
Vladimirova, Valentina
Solbach, Christine
Karn, Thomas
Ataseven, Beyhan
Sinn, Bruno Valentin
Barinoff, Jana
Müller, Volkmar
Blohmer, Jens-Uwe
Schem, Christian
Engels, Knut
Marmé, Frederik
Fisseler-Eckhoff, Annette
Fasching, Peter A.
Stickeler, Elmar
van Mackelenbergh, Marion
Denkert, Carsten
Stenzinger, Albrecht
Loibl, Sibylle
Gröschel, Stefan
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (DKFZ)
Article History
Received: 14 June 2021
Accepted: 16 September 2022
First Online: 5 October 2022
Declarations
:
: All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki or comparable ethical standards. Ethical approval was obtained for all clinical centers and from the institutional review board of the Charité-Universitätsmedizin Berlin, Germany. All patients provided written informed consent for study participation, biomaterial, and data collection.
: Not applicable.
: CD reported stock and other ownership interests from Sividon Diagnostics (until 2016); honoraria from Novartis, Roche, MSD Oncology, Daiichi Sankyo, Molecular Health, AstraZeneca, Merck; research funding from Myriad Genetics and Roche; Travel, Accommodations, Expenses frpm Roche; patents, royalties other intellectual property from VMScope digital pathology software; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; Patent application WO2020109570A1—cancer immunotherapy. VM reported personal fees from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva, Seagen and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro, Nektar, personal fees from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro and Nektar, other from Novartis, Roche, Seattle Genetics, Genentech, outside the submitted work. BA reported personal fees and non-financial support from Roche, personal fees from Amgen, personal fees from AstraZeneca, personal fees and non-financial support from Tesaro/GSK, personal fees from Clovis, personal fees from Celgene, non-financial support from PharmaMar, personal fees and non-financial support from MSD, personal fees from Novartis, outside the submitted work. AS reported advisory board/speaker's bureau from Astra Zeneca, AGCT, Bayer, BMS, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, Thermo Fisher; research grants from Bayer, BMS, Chugai, outside the submitted work. SL reported research grants paid to the institution from Abbvie, Amgen, Roche, Celgene, Novartis, Pfizer, other from SeaGen, grants from Immunomedics, other from Prime/Medscape, other from Eirgenix, grants, personal fees and other from DSI, other from BMS, other from Merck, other from Puma, personal fees from Chugai, outside the submitted work; In addition, Dr. Loibl has a patent EP14153692.0 pending. PAF reported personal fees from Novartis, grants from Biontech, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from Seattle Genetics, personal fees from Roche, personal fees from Hexal, during the conduct of the study. MvM reported personal fees from Amgen, AstraZeneca, Genomic Health, Mylan, Novartis, Pfizer, Pierre Fabre, Roche. FM reported grants from AstraZeneca, personal fees from AstraZeneca, MSD, Clovis, GSK/Tesaro, Pfizer, Novartis, Lilly, Roche, Celgene, Seagen, Myriad, PharmaMar, Eisai, Janssen-Cilag. JUB reported grants from Sysmex, Somatex; personal fees from Amgen, Astra-Zeneca, Lilly, MSD, Novartis, Pfizer, Roche, SonoScape, Sysmex. Other authors have no competing interest.